Immunology and skin cancer

Andreea Grosu-Bularda, Luana Lăzărescu, Alexandru Stoian, Ioan Lascăr

Abstract


Skin cancer represents the most frequent type of human malignancy. Skin poses an important immunologic role, therefore also the correlation between skin cancer development and immunologic mechanisms are intensely studied. These aspects are of the utmost importance in patients requiring immunosuppressive therapy as transplant recipients or immunologic disorders. Cancer development after organ transplantation is the result of intense intercommunication between immunological and non-immunological factors. Non-immunologic risk factors like individual predisposition, sun and environmental exposure are a contributing part to the skin neoplasia incidence. In addition, continuous exposure to immunosuppressive medication is closely linked to the development of the new malignancy. A similar situation is encountered in autoimmune diseases, those patients having an increased risk of skin cancer, especially squamous cell carcinoma. Immunotherapy shows promising results and encourages further studies in this direction. Also, an important aspect is to support preventive strategies in patients with high risk of skin cancer development.


Keywords


skin cancer; immune response; immunosuppressant therapy; transplant; autoimmune disease

Full Text:

PDF

References


Rogers HW, Weinstock MA, Feldman SR, Coldiron BM. Incidence estimate of nonmelanoma skin cancer (keratinocyte carcinomas) in the US population, 2012. JAMA Dermatol 2015; 151(10):1081–1086.

Rangwala S, Tsai KY. Roles of the immune system in skin cancer. Br J Dermatol 2011; 165 (5):953-965.

Karimkhani C, Boyers LN, Dellavalle RP, Weinstock MA. It's time for "keratinocyte carcinoma" to replace the term "non-melanoma skin cancer". J Am Acad Dermatol 2015; 72(1):186-187.

Elder DE, Massi D, Scolyer RA, Willemze R (Eds). WHO Classification of Tumors, 4th Edition, Volume 11; 2018 [http://publications.iarc.fr/Book-And-Report-Series/Who-Iarc-Classification-Of-Tumours available at 09/29/2018]

Tai P, Au J. Skin cancer management-updates on Merkel cell carcinoma. Ann Transl Med 2018; 6(14):282.

Burton KA, Ashack KA, Khachemoune A. Cutaneous squamous cell carcinoma: A review of high-risk and metastatic disease. Am J Clin Dermatol 2016; 17(5):491-508.

Chung S. Basal cell carcinoma. Arch Plast Surg 2012; 39(2):166-170.

Gurudutt VV, Genden EM. Cutaneous squamous cell carcinoma of the head and neck. J Skin Cancer 2011; 2011:502723.

Que SKT, Zwald FO, Schmults CD. Cutaneous squamous cell carcinoma: Incidence, risk factors, diagnosis, and staging. J Am Acad Dermatol 2018; 78(2):237-247.

Gerlini G, Romagnoli P, Pimpinelli N. Skin cancer and immunosuppression. Crit Rev Oncol Hematol 2005; 56(1):127-136.

Ali Z, Yousaf N, Larkin J. Melanoma epidemiology, biology and prognosis. EJC Suppl 2013; 11(2):81-91.

Ridky TW. Nonmelanoma skin cancer. J Am Acad Dermatol 2007; 57(3):484–501.

Schadendorf D, Lebbé C, Zur Hausen A, et al. Merkel cell carcinoma: Epidemiology, prognosis, therapy and unmet medical needs. Eur J Cancer 2017; 71:53-69.

Bos JD, Luiten RM. Skin immune system. In: Stockfleth E, Ulrich C (Eds.) Skin cancer after organ transplantation. cancer treatment and research, Volume 146. Boston: Springer; 2009: 45-63.

Streilein JW. Skin-associated lymphoid tissues (SALT): origins and functions. J Invest Dermatol 1983; 80(Suppl):12s-16s.

Mittal D, Gubin MM, Schreiber RD, Smyth MJ. New insights into cancer immunoediting and its three component phases-elimination, equilibrium and escape. Curr Opin Immunol 2014; 27:16-25.

Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002; 3(11):991-998.

Wadström J, Ericzon BG, Halloran PF, et al. Advancing transplantation: new questions, new possibilities in kidney and liver transplantation. Transplantation 2017; 101(Suppl 2S):S1-S41.

Organ donation and Transplantation Activities 2015, in Global Database on Donation and Transplantation [http://www.transplant-observatory.org/ available at 09/29/2018]

Siemionow M. Vascularized composite allotransplantation: a new concept in musculoskeletal regeneration. J Mater Sci Mater Med 2015; 26(12):266.

Diaz-Siso JR, Bueno EM, Sisk GC, Marty FM, Pomahac B, Tullius SG. Vascularized composite tissue allotransplantation - State of the art. Clin Ttransplant 2013; 27(3):330-337.

Chapman JR, Webster AC, Wong G. Cancer in the transplant recipient. Cold Spring Harb Perspect Med 2013; 3(7):a015677.

Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med 2003; 348(17):1681-1691.

Dantal J. De Novo Post-Transplantation Malignancies: Incidence and Risk Factors. In: Stockfleth E, Ulrich C (Eds.) Skin Cancer after Organ Transplantation. Cancer Treatment and Research. Volume 146. Boston: Springer; 2009: 11-21.

White MK, Pagano JS, Khalili K. Viruses and human cancers: a long road of discovery of molecular paradigms. Clin Microbiol Rev 2014; 27(3):463-481.

Mittal A, Colegio OR. Skin cancers in organ transplant recipients. Am J Transplant 2017; 17(10):2509-2530.

Martinez OM, Rosen HR. Basic concepts in transplant immunology. Liver Transpl 2005; 11(4):370-381.

Friedman O, Carmel N, Sela M, et al. Immunological and inflammatory mapping of vascularized composite allograft rejection processes in a rat model. PLoS ONE 2017; 12(7):e0181507.

Howsare M, Jones CM, Ramirez AM. Immunosuppression maintenance in vascularized composite allotransplantation: what is just right? Curr Opin Organ Transplant 2017; 22(5):463-469.

Sinha I, Pomahac B. Split Rejection in vascularized composite allotransplantation. Eplasty 2013; 13:e53.

Gallagher MP, Kelly PJ, Jardine M, et al. Long-term cancer risk of immunosuppressive regimens after kidney transplantation. J Am Soc Nephrol 2010; 21(5):852-858.

Morelon E, Petruzzo P, Kanitakis J. Chronic rejection in vascularized composite allotransplantation. Curr Opin Organ Transplant 2018; 23(5):582-591.

Perrett CM, Harwood CA, McGregor JM, Karran P. Carcinogenic Mechanisms Related to Immunosuppressive Therapy. In: Stockfleth E, Ulrich C (Eds.) Skin Cancer after Organ Transplantation. Cancer Treatment and Research, Volume 146. Boston: Springer; 2009: 123-132.

Coghill AE, Johnson LG, Berg D, Resler AJ, Leca N, Madeleine MM. Immunosuppressive medications and squamous cell skin carcinoma: nested case-control study within the Skin Cancer after Organ Transplant (SCOT) cohort. Am J Transplant 2016; 16(2):565-573.

Kostaki D, Antonini A, Peris K, Fargnoli MC. Skin cancer risk in autoimmune connective tissue diseases. G Ital Dermatol Venereol 2014; 149(5):567-572.

Tao J, Zhang X, Guo N, et al. Squamous cell carcinoma complicating discoid lupus erythematosus in Chinese patients: review of the literature, 1964-2010. J Am Acad Dermatol 2012; 66(4):695-696.

Wooten M. Systemic sclerosis and malignancy: a review of the literature. South Med J 2008; 101(1):59–62.

Zeineddine N, Khoury LE, Mosak J. Systemic sclerosis and malignancy: A review of current data. J Clin Med Res 2016; 8(9):625-632.

Bogdanov I, Kazandjieva J, Darlenski R, Tsankov N. Dermatomyositis: Current concepts. Clin Dermatol 2018; 36(4):450-458.

Teh LS, Lai J-C, Lian JC. Rapidly developed multiple face and neck skin cancers in a patient with Sjögren’s syndrome: A case report. Am J Case Rep 2017; 18:347-350.

Lazarus MN, Robinson D, Mak V, et al. Incidence of cancer in a cohort of patients with primary Sjögren’s syndrome. Rheumatology (Oxford) 2006; 45:1012–1015.

Leung J, Dowling L, Obadan I, et al. Risk of non-melanoma skin cancer in autoimmune hepatitis. Dig Dis Sci 2010; 55(11):3218-3223.

Lanoy E, Engels EA. Skin cancers associated with autoimmune conditions among elderly adults. Br J Cancer 2010; 103(1):112-114.

Nitsan Z, Kucuk N, Appel S, Tichmanovich N, Osherov M, Milo R. Mycosis fungoides - A cutaneous lymphoproliferative disorder in a patient treated with fingolimod for multiple sclerosis. J Clin Neurosci 2018; 48:102-103.

McCarthy EF. The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas. Iowa Orthop J 2006; 26:154-158.

Coley WB. The treatment of malignant tumors by repeated inoculations of erysipelas: with a report of ten original cases. Am J Med Sci 1893; 105:487-511.

Urban JL, Schreiber H. Tumor antigens. Annu Rev Immunol 1992; 10:617-644.

Showalter A, Limaye A, Oyer JL, et al. Cytokines in immunogenic cell death: applications for cancer immunotherapy. Cytokine 2017; 97:123-132.

Sabado RL, Balan S, Bhardwaj N. Dendritic cell-based immunotherapy. Cell Research 2017; 27(1):74-95.

Mocellin S, Pasquali S, Rossi CR, et al. Interferon alpha adjuvant therapy in patients with high risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst 2010; 102:493–501.

Tsai KY. Systemic adjuvant therapy for patients with high-risk melanoma. Arch Dermatol 2007; 143:779–782.

Sadozai H, Gruber T, Hunger RE, Schenk M. Recent successes and future directions in immunotherapy of cutaneous melanoma. Front Immunol 2017; 8:1617.

Eggermont AM, Suciu S, Testori A, et al. Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. J Clin Oncol 2012; 30(31):3810-3818.

Petrella T, Quirt I, Verma S et al. Single-agent interleukin-2 in the treatment of metastatic melanoma: a systematic review. Cancer Treat Rev 2007; 33(5):484–496.

Mouawad R, Sebert M, Michels J, Bloch J, Spano JP, Khayat D. Treatment for metastatic malignant melanoma: old drugs and new strategies. Crit Rev Oncol Hematol 2010; 74(1):27-39.

Seidel JA, Otsuka A, Kabashima K. Anti-PD-1 and anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations. Front Oncol 2018; 8:86.

Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with Ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363(8):711-723.

Faries MB, Morton DL. Therapeutic vaccines for melanoma: current status. Bio Drugs 2005; 19(4):247-260.

Dalgleish AG. Therapeutic cancer vaccines: why so few randomized Phase III studies reflect the initial optimism of Phase II studies. Vaccine 2011; 29(47):8501–8505.

Perica K, Varela JC, Oelke M, Schneck J. Adoptive T cell immunotherapy for cancer. Rambam Maimonides Med J 2015; 6(1):e0004.

Johnson LA, Morgan RA, Dudley ME, et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 2009; 114(3):535-546.

Berman B. Imiquimod: a new immune response modifier for the treatment of external genital warts and other diseases in dermatology. Int J Dermatol 2002; 41(Suppl 1):7-11.

Neville JA, Welch E, Leffell DJ. Management of nonmelanoma skin cancer in 2007. Nat Clin Pract Oncol 2007; 4(8): 462–469.

Gaspari AA, Sauder DN. Immunotherapy of basal cell carcinoma: evolving approaches. Dermatol Surg 2003; 29(10):1027–1034.

Stallone G, Infante B, Grandaliano G. Management and prevention of post-transplant malignancies in kidney transplant recipients. Clin Kidney J 2015; 8(5):637-644.

Tunçer Vural A, Karataş Toğral A, Kırnap M, Güleç AT, Haberal M. Skin cancer risk awareness and sun-protective behavior among solid-organ transplant recipients. Exp Clin Transplant 2018; 16 Suppl 1(Suppl 1):203-207.

Wu SZ, Jiang P, DeCaro JE, Bordeaux JS. A qualitative systematic review of the efficacy of sun protection education in organ transplant recipients. J Am Acad Dermatol 2016; 75(6):1238-1244.




Copyright (c) 2018 Andreea Grosu-Bularda, Luana Lăzărescu, Alexandru Stoian, Ioan Lascăr

Creative Commons License
Archive of Clinical Cases is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

 

ISSN: 2360-6975